Holly Algood
Last active: 11/3/2016

Profile

Dr. Algood's lab researches the body’s immune response to Helicobacter pylori, a pathogen which can lead to peptic ulcers and gastric cancer. Ongoing projects in her laboratory are at the cross roads of chronic inflammation and T cell responses, macrophage polarization, bacterial pathogenesis, and innate immunity (including nutritional immunity). Her long-term research interests involve understanding the interactions between disease-causing pathogens, the immune system, and normal microbes found inside the human body.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. IL-17a and IL-22 Induce Expression of Antimicrobials in Gastrointestinal Epithelial Cells and May Contribute to Epithelial Cell Defense against Helicobacter pylori. Dixon BR, Radin JN, Piazuelo MB, Contreras DC, Algood HM (2016) PLoS One 11(2): e0148514
    › Primary publication · 26867135 (PubMed) · PMC4750979 (PubMed Central)
  2. Helicobacter pylori Resists the Antimicrobial Activity of Calprotectin via Lipid A Modification and Associated Biofilm Formation. Gaddy JA, Radin JN, Cullen TW, Chazin WJ, Skaar EP, Trent MS, Algood HM (2015) MBio 6(6): e01349-15
    › Primary publication · 26646009 (PubMed) · PMC4669380 (PubMed Central)
  3. Helicobacter pylori adaptation in vivo in response to a high-salt diet. Loh JT, Gaddy JA, Algood HM, Gaudieri S, Mallal S, Cover TL (2015) Infect Immun 83(12): 4871-83
    › Primary publication · 26438795 (PubMed) · PMC4645402 (PubMed Central)
  4. The host protein calprotectin modulates the Helicobacter pylori cag type IV secretion system via zinc sequestration. Gaddy JA, Radin JN, Loh JT, Piazuelo MB, Kehl-Fie TE, Delgado AG, Ilca FT, Peek RM, Cover TL, Chazin WJ, Skaar EP, Scott Algood HM (2014) PLoS Pathog 10(10): e1004450
    › Primary publication · 25330071 (PubMed) · PMC4199781 (PubMed Central)
  5. CD8αα⁺ innate-type lymphocytes in the intestinal epithelium mediate mucosal immunity. Van Kaer L, Algood HMS, Singh K, Parekh VV, Greer MJ, Piazuelo MB, Weitkamp JH, Matta P, Chaturvedi R, Wilson KT, Olivares-Villagómez D (2014) Immunity 41(3): 451-464
    › Primary publication · 25220211 (PubMed) · PMC4169715 (PubMed Central)
  6. Systems modeling of the role of interleukin-21 in the maintenance of effector CD4+ T cell responses during chronic Helicobacter pylori infection. Carbo A, Olivares-Villagómez D, Hontecillas R, Bassaganya-Riera J, Chaturvedi R, Piazuelo MB, Delgado A, Washington MK, Wilson KT, Algood HM (2014) MBio 5(4): e01243-14
    › Primary publication · 25053783 (PubMed) · PMC4120195 (PubMed Central)
  7. Role of connexin 43 in Helicobacter pylori VacA-induced cell death. Radin JN, González-Rivera C, Frick-Cheng AE, Sheng J, Gaddy JA, Rubin DH, Algood HM, McClain MS, Cover TL (2014) Infect Immun 82(1): 423-32
    › Primary publication · 24191302 (PubMed) · PMC3911829 (PubMed Central)
  8. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, Braun N, Taylor T, Pandit KV, Aboud C, Yu C, Kaminski N, Boyd AS, King LE (2013) JAMA Dermatol 149(9): 1040-9
    › Primary publication · 23863960 (PubMed) · PMC3927541 (PubMed Central)
  9. In vitro induction of regulatory CD4+CD8α+ T cells by TGF-β, IL-7 and IFN-γ. Van Kaer L, Rabacal WA, Scott Algood HM, Parekh VV, Olivares-Villagómez D (2013) PLoS One 8(7): e67821
    › Primary publication · 23844100 (PubMed) · PMC3701067 (PubMed Central)
  10. Flagellar localization of a Helicobacter pylori autotransporter protein. Radin JN, Gaddy JA, González-Rivera C, Loh JT, Algood HM, Cover TL (2013) MBio 4(2): e00613-12
    › Primary publication · 23572556 (PubMed) · PMC3622936 (PubMed Central)
  11. High dietary salt intake exacerbates Helicobacter pylori-induced gastric carcinogenesis. Gaddy JA, Radin JN, Loh JT, Zhang F, Washington MK, Peek RM, Algood HM, Cover TL (2013) Infect Immun 81(6): 2258-67
    › Primary publication · 23569116 (PubMed) · PMC3676043 (PubMed Central)
  12. The interleukin-17 receptor B subunit is essential for the Th2 response to Helicobacter pylori, but not for control of bacterial burden. Horvath DJ, Radin JN, Cho SH, Washington MK, Algood HM (2013) PLoS One 8(3): e60363
    › Primary publication · 23533678 (PubMed) · PMC3606319 (PubMed Central)
  13. The intermediate region of Helicobacter pylori VacA is a determinant of toxin potency in a Jurkat T cell assay. González-Rivera C, Algood HM, Radin JN, McClain MS, Cover TL (2012) Infect Immun 80(8): 2578-88
    › Primary publication · 22585965 (PubMed) · PMC3434591 (PubMed Central)
  14. IL-23 Contributes to Control of Chronic Helicobacter Pylori Infection and the Development of T Helper Responses in a Mouse Model. Horvath DJ, Washington MK, Cope VA, Algood HM (2012) Front Immunol : 56
    › Primary publication · 22566937 (PubMed) · PMC3342083 (PubMed Central)
  15. Intestinal epithelial cells modulate CD4 T cell responses via the thymus leukemia antigen. Olivares-Villagómez D, Algood HM, Singh K, Parekh VV, Ryan KE, Piazuelo MB, Wilson KT, Van Kaer L (2011) J Immunol 187(8): 4051-60
    › Primary publication · 21900182 (PubMed) · PMC3186831 (PubMed Central)
  16. KSR1 protects from interleukin-10 deficiency-induced colitis in mice by suppressing T-lymphocyte interferon-γ production. Goettel JA, Scott Algood HM, Olivares-Villagómez D, Washington MK, Chaturvedi R, Wilson KT, Van Kaer L, Polk DB (2011) Gastroenterology 140(1): 265-74
    › Primary publication · 20875416 (PubMed) · PMC3008308 (PubMed Central)
  17. Helicobacter pylori induces ERK-dependent formation of a phospho-c-Fos c-Jun activator protein-1 complex that causes apoptosis in macrophages. Asim M, Chaturvedi R, Hoge S, Lewis ND, Singh K, Barry DP, Algood HS, de Sablet T, Gobert AP, Wilson KT (2010) J Biol Chem 285(26): 20343-57
    › Primary publication · 20410304 (PubMed) · PMC2888446 (PubMed Central)
  18. Analysis of a beta-helical region in the p55 domain of Helicobacter pylori vacuolating toxin. Ivie SE, McClain MS, Algood HM, Lacy DB, Cover TL (2010) BMC Microbiol : 60
    › Primary publication · 20178613 (PubMed) · PMC2836311 (PubMed Central)
  19. Regulation of gastric B cell recruitment is dependent on IL-17 receptor A signaling in a model of chronic bacterial infection. Algood HM, Allen SS, Washington MK, Peek RM, Miller GG, Cover TL (2009) J Immunol 183(9): 5837-46
    › Primary publication · 19812196 (PubMed) · PMC2834183 (PubMed Central)
  20. Helicobacter pylori HopQ outer membrane protein attenuates bacterial adherence to gastric epithelial cells. Loh JT, Torres VJ, Algood HM, McClain MS, Cover TL (2008) FEMS Microbiol Lett 289(1): 53-8
    › Primary publication · 19065710 (PubMed) · PMC2651568 (PubMed Central)
  21. Helicobacter pylori VacA subdomain required for intracellular toxin activity and assembly of functional oligomeric complexes. Ivie SE, McClain MS, Torres VJ, Algood HM, Lacy DB, Yang R, Blanke SR, Cover TL (2008) Infect Immun 76(7): 2843-51
    › Primary publication · 18443094 (PubMed) · PMC2446698 (PubMed Central)
  22. Host response to Helicobacter pylori infection before initiation of the adaptive immune response. Algood HM, Gallo-Romero J, Wilson KT, Peek RM, Cover TL (2007) FEMS Immunol Med Microbiol 51(3): 577-86
    › Primary publication · 17919297 (PubMed)
  23. L-arginine availability regulates inducible nitric oxide synthase-dependent host defense against Helicobacter pylori. Chaturvedi R, Asim M, Lewis ND, Algood HM, Cover TL, Kim PY, Wilson KT (2007) Infect Immun 75(9): 4305-15
    › Primary publication · 17562760 (PubMed) · PMC1951193 (PubMed Central)
  24. Resistance of primary murine CD4+ T cells to Helicobacter pylori vacuolating cytotoxin. Algood HM, Torres VJ, Unutmaz D, Cover TL (2007) Infect Immun 75(1): 334-41
    › Primary publication · 17074854 (PubMed) · PMC1828377 (PubMed Central)
  25. Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses. Algood HM, Cover TL (2006) Clin Microbiol Rev 19(4): 597-613
    › Primary publication · 17041136 (PubMed) · PMC1592695 (PubMed Central)
  26. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Algood HM, Lin PL, Flynn JL (2005) Clin Infect Dis : S189-93
    › Primary publication · 15983898 (PubMed)
  27. CCR5-deficient mice control Mycobacterium tuberculosis infection despite increased pulmonary lymphocytic infiltration. Algood HM, Flynn JL (2004) J Immunol 173(5): 3287-96
    › Primary publication · 15322191 (PubMed)
  28. TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. Algood HM, Lin PL, Yankura D, Jones A, Chan J, Flynn JL (2004) J Immunol 172(11): 6846-57
    › Primary publication · 15153503 (PubMed)
  29. Chemokines and tuberculosis. Algood HM, Chan J, Flynn JL (2003) Cytokine Growth Factor Rev 14(6): 467-77
    › Primary publication · 14563349 (PubMed)
  30. Mycobacterium tuberculosis in chemokine receptor 2-deficient mice: influence of dose on disease progression. Scott HM, Flynn JL (2002) Infect Immun 70(11): 5946-54
    › Primary publication · 12379669 (PubMed) · PMC130313 (PubMed Central)
  31. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Peters W, Scott HM, Chambers HF, Flynn JL, Charo IF, Ernst JD (2001) Proc Natl Acad Sci U S A 98(14): 7958-63
    › Primary publication · 11438742 (PubMed) · PMC35450 (PubMed Central)
  32. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, Tsai MM, Flynn JL, Chan J (2001) Infect Immun 69(3): 1847-55
    › Primary publication · 11179363 (PubMed) · PMC98092 (PubMed Central)